Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Guardant Health, Inc. Stock Research

GH

27.62USD+1.82(+7.05%)Market Closed
Watchlist

Market Summary

USD27.62+1.82
Market Closed
7.05%

GH Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

GH Stock Price

GH RSI Chart

GH Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-6.39

Price/Sales (Trailing)

6.37

EV/EBITDA

-6.43

Price/Free Cashflow

-8.48

GH Price/Sales (Trailing)

GH Profitability

EBT Margin

-137.61%

Return on Equity

-1.1K%

Return on Assets

-43.99%

Free Cashflow Yield

-11.79%

GH Fundamentals

GH Revenue

Revenue (TTM)

510.2M

Revenue Y/Y

25.66%

Revenue Q/Q

6.55%

GH Earnings

Earnings (TTM)

-508.2M

Earnings Y/Y

68.28%

Earnings Q/Q

45.5%

Price Action

52 Week Range

20.6762.75
(Low)(High)

Last 7 days

0.7%

Last 30 days

-27.7%

Last 90 days

-23.9%

Trailing 12 Months

-44.3%

GH Financial Health

Current Ratio

5.41

GH Investor Care

Shares Dilution (1Y)

15.30%

Diluted EPS (TTM)

-4.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for GH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Bell Michael Brian
sold (taxes)
-12,609
29.53
-427
chief financial officer
2023-09-15
Bell Michael Brian
acquired
-
-
1,233
chief financial officer
2023-09-15
POTTER MYRTLE S
acquired
-
-
69.00
-
2023-09-12
Kalia Kumud
sold
-69,253
32.59
-2,125
chief information officer
2023-09-09
Kalia Kumud
sold (taxes)
-76,308
33.72
-2,263
chief information officer
2023-09-09
Saia John G.
sold (taxes)
-10,183
33.72
-302
chief legal officer
2023-09-09
Kalia Kumud
acquired
-
-
6,544
chief information officer
2023-09-09
Chudova Darya
acquired
-
-
2,908
chief technology officer
2023-09-09
Chudova Darya
sold (taxes)
-33,922
33.72
-1,006
chief technology officer
2023-09-09
Merrill Amelia
sold (taxes)
-12,240
33.72
-363
svp, people

1–10 of 50

Which funds bought or sold GH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
reduced
-21.56
120,682
2,703,770
0.02%
2023-09-21
Baystate Wealth Management LLC
new
-
2,864
2,864
-%
2023-09-20
BARCLAYS PLC
added
33.08
3,691,000
7,264,000
-%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
149
430
-%
2023-09-07
Triatomic Management LP
reduced
-42.97
-106,088
716,000
0.73%
2023-09-06
Deep Track Capital, LP
new
-
53,700,000
53,700,000
2.49%
2023-08-24
Adalta Capital Management LLC
reduced
-0.85
987,000
2,906,000
1.94%
2023-08-23
Stonebridge Capital Advisors LLC
new
-
1,969
1,969
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
118
799,796
1,142,020
0.01%
2023-08-22
COMERICA BANK
new
-
64,000
64,000
0.01%

1–10 of 37

Latest Funds Activity

Are funds buying GH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GH
No. of Funds

Schedule 13G FIlings of Guardant Health

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
viking global investors lp
4.0%
4,107,644
SC 13G/A
Feb 13, 2023
capital international investors
7.7%
7,879,355
SC 13G
Feb 13, 2023
capital research global investors
2.0%
2,001,782
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.83%
9,040,240
SC 13G/A
Feb 03, 2023
blackrock inc.
5.4%
5,495,293
SC 13G
Mar 09, 2022
blackrock inc.
4.9%
4,961,865
SC 13G/A
Feb 11, 2022
capital research global investors
7.8%
7,927,702
SC 13G
Feb 10, 2022
fmr llc
-
0
SC 13G/A

Recent SEC filings of Guardant Health

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading
Sep 12, 2023
144
Notice of Insider Sale Intent
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 07, 2023
8-K
Current Report
Sep 06, 2023
4
Insider Trading

Peers (Alternatives to Guardant Health)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
67.5B
61.9B
-10.91% 34.15%
11.69
1.09
3.02% -11.37%
18.2B
14.1B
-3.48% -0.57%
21.87
1.29
-5.68% -58.27%
13.8B
9.5B
-6.83% 1.44%
17.41
1.46
-10.34% -46.50%
MID-CAP
8.7B
13.8B
-6.62% 41.44%
12.58
0.63
5.76% -10.75%
6.7B
4.6B
-4.11% 45.48%
21.27
1.46
9.56% -4.24%
5.2B
3.4B
-5.62% 16.47%
21.63
1.54
20.66% 17.86%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
3.2B
510.2M
-27.73% -44.30%
-6.39
6.37
25.00% 4.56%
3.1B
4.4B
-5.01% -18.52%
9.85
0.72
-16.06% -30.43%
3.0B
2.2B
-0.58% -8.34%
1.3K
1.36
0.61% -98.34%
SMALL-CAP
1.9B
1.5B
-9.98% 59.13%
-149.89
1.27
12.20% -155.34%
737.9M
3.0B
-6.00% -10.91%
-7.16
0.25
11.66% -12.20%
68.5M
71.0M
-13.21% -34.29%
-1.5
0.97
-36.38% -594.74%
42.7M
52.9M
1.20% -5.95%
-1.21
0.81
23.27% 10.26%
21.3M
23.6M
-14.52% -42.66%
-11.24
0.9
-9.62% -60.46%

Guardant Health News

Nasdaq
Piper Sandler Upgrades Guardant Health (GH).
Nasdaq,
8 hours ago
Digital Journal

Returns for GH

Cumulative Returns on GH

-37.2%


3-Year Cumulative Returns

Risks for GH

What is the probability of a big loss on GH?

96.9%


Probability that Guardant Health stock will be more than 20% underwater in next one year

85.4%


Probability that Guardant Health stock will be more than 30% underwater in next one year.

60%


Probability that Guardant Health stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.

Drawdowns

Financials for Guardant Health

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.8%510,159,000482,153,000449,538,000430,755,000408,130,000391,087,000373,653,000343,861,000323,651,000297,885,000286,730,000271,311,000257,590,000245,230,000214,375,000184,351,000145,195,000110,602,00090,639,00077,768,00067,208,000
  S&GA Expenses-0.8%308,959,000311,519,000299,828,000278,004,000247,862,000221,975,000191,881,000163,570,000138,437,000115,736,000106,513,00097,512,00091,219,00085,643,00078,335,00073,162,00067,824,00059,960,00053,465,00045,907,00040,251,000
  R&D Expenses1.3%390,082,000385,178,000373,807,000340,250,000311,201,000289,470,000263,221,000230,482,000195,759,000168,354,000149,862,000135,455,000123,779,000106,992,00086,292,00077,069,00066,753,00058,775,00050,714,00042,182,00035,175,000
EBITDA100.0%--621,807,000-614,910,000-551,958,000-501,772,000-374,508,000-359,622,000-378,569,000-344,577,000-298,166,000-225,073,000-160,460,000-103,279,000-66,952,000-57,131,000------
EBITDA Margin100.0%--1.29-1.37-1.28-1.23-0.96-0.96-1.10-1.06-1.00-0.78-0.59-0.40-0.27-0.27------
Interest Expenses0%2,577,0002,577,0002,577,0002,576,0002,576,0002,575,0002,577,0006,670,0006,034,0005,400,0004,766,000351,000623,000900,0001,181,0001,159,0001,183,0001,213,0001,251,0001,256,0001,255,000
Earnings Before Taxes23.6%-506,779,000-663,490,000-653,449,000-586,417,000-531,968,000-400,474,000-384,470,000-404,952,000-369,124,000-321,337,000-245,904,000-175,721,000-117,411,000-80,213,000-69,723,000-72,361,000-82,577,000-91,706,000-84,225,000-74,041,000-79,123,000
EBT Margin100.0%--1.38-1.45-1.36-1.30-1.02-1.03-1.18-1.14-1.08-0.86-0.65-0.46-0.33-0.33------
Net Income23.6%-508,232,000-664,893,000-654,588,000-586,965,000-532,497,000-400,640,000-384,770,000-405,504,000-369,648,000-321,812,000-246,283,000-175,348,000-116,768,000-78,329,000-67,851,000-71,013,000-81,431,000-91,770,000-84,263,000-74,051,000-79,133,000
Net Income Margin100.0%--1.38-1.46-1.36-1.30-1.02-1.03-1.18-1.14-1.08-0.86-0.68-0.48-0.35-0.35------
Free Cashflow100.0%--417,570,000-386,924,000-387,787,000-363,195,000-309,494,000-284,052,000-248,944,000-191,493,000-143,097,000-140,100,000-111,026,000-97,712,000-81,723,000-65,851,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32017Q4
Assets21.7%1,8401,5121,6101,7021,8542,1302,2042,2262,2922,3472,2721,2621,278948963948940579587345343
  Current Assets26.5%1,3981,1041,1921,1311,0371,1131,1141,5931,8912,0331,8881,0871,010607597583604512469297243
    Cash Equivalents21.2%27122414215821557449283293986983314316515214314717515414111473.00
  Inventory30.2%61.0046.0052.0063.0060.0037.0031.0025.0026.0029.0023.0028.0020.0025.0015.0015.0014.0010.009.007.007.00
  Net PPE-4.6%15616316816816315112410690.0072.0063.0062.0057.0047.0044.0041.0035.0031.0031.0030.0016.00
  Goodwill0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00-----
Liabilities-0.6%1,5471,5561,5501,5351,5351,5971,5591,4571,4441,44091611411311811586.0078.0065.0062.0047.0034.00
  Current Liabilities-1.6%20120419317516822919510297.0096.0067.0072.0070.0082.0073.0068.0057.0048.0047.0032.0020.00
Shareholder's Equity757.1%293-44.5560.001673195336457097888471,2981,0921,115785798815815468483255309
  Retained Earnings-4.1%-1,868-1,795-1,662-1,522-1,360-1,131-1,007-916-809-711-606-512-435-380-352-327-314-303-280-255-195
  Additional Paid-In Capital23.0%2,1701,7641,7421,7161,7041,6821,6581,6271,5971,5581,9021,6011,5441,1581,1501,1421,12977176411.005.00
Shares Outstanding14.6%11810310310210210210210110110110010096.0094.0094.0093.0089.0086.0030.0012.0013.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations5.0%-337-355-309-295-270-221-209-191-146-106-103-75.05-65.64-56.11-47.13-43.33-66.72-69.93-72.18-63.64-55.45
  Share Based Compensation-3.5%89.0092.0095.0098.0011212115118120219314492.0043.0020.0017.0014.0011.009.007.006.005.00
Cashflow From Investing-85.7%28.00196150-187-276-76.22-63.15-94.14-61.40-514-617-296-317-312-317-538-478-146-153-51.16-100
Cashflow From Financing292.7%366-189-189-187-1733.00-66.829769821,3391,41036737336636761560929429343.0056.00
  Buy Backs-------------------0.000.000.00

GH Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Precision oncology testing$ 125,244$ 92,062$ 238,637$ 176,198
Development services and other11,90617,08227,22729,045
Total revenue137,150109,144265,864205,243
Costs and operating expenses:    
Cost of precision oncology testing49,35734,37594,46365,059
Cost of development services and other4,4912,35212,4583,649
Research and development expense90,35985,455183,487167,212
Sales and marketing expense71,04373,603147,166138,035
General and administrative expense41,51643,68081,96184,947
Total costs and operating expenses256,766239,465519,535458,902
Loss from operations(119,616)(130,321)(253,671)(253,659)
Interest income6,7271,3879,7872,165
Interest expense(645)(645)(1,289)(1,289)
Other income (expense), net41,25937839,605330
Fair value adjustments of noncontrolling interest liability0(99,785)0(99,785)
Loss before provision for income taxes(72,275)(228,986)(205,568)(352,238)
Provision for income taxes496446736422
Net loss$ (72,771)$ (229,432)$ (206,304)$ (352,660)
Net loss per share, basic (in usd per share)$ (0.67)$ (2.25)$ (1.95)$ (3.46)
Net loss per share, diluted (in usd per share)$ (0.67)$ (2.25)$ (1.95)$ (3.46)
Weighted-average shares used in computing net loss per share , basic (in shares)108,808102,047105,752101,950
Weighted-average shares used in computing net loss per share, diluted (in shares)108,808102,047105,752101,950

GH Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 271,073$ 141,647
Short-term marketable debt securities953,776869,584
Accounts receivable, net86,46897,256
Inventory, net60,52951,598
Prepaid expenses and other current assets, net25,80931,509
Total current assets1,397,6551,191,594
Property and equipment, net155,741167,920
Right-of-use assets, net165,273174,001
Intangible assets, net10,36111,727
Goodwill3,2903,290
Other assets, net107,69761,453
Total Assets1,840,0171,609,985
Current liabilities:  
Accounts payable and accrued liabilities188,696175,817
Deferred revenue12,23717,403
Total current liabilities200,933193,220
Convertible senior notes, net1,138,6781,137,391
Long-term operating lease liabilities198,230210,015
Other long-term liabilities9,4509,179
Total Liabilities1,547,2911,549,805
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 202200
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2023, and December 31, 2022; 117,662,134 and 102,619,383 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively11
Additional paid-in capital2,169,9111,742,114
Accumulated other comprehensive loss(8,469)(19,522)
Accumulated deficit(1,868,717)(1,662,413)
Total Stockholders’ Equity292,72660,180
Total Liabilities and Stockholders’ Equity$ 1,840,017$ 1,609,985
Helmy Eltoukhy
1370
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.